Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection

Christoph Boesecke; Patrick Ingiliz; Florian Berger; Thomas Lutz; Knud Schewe; Julian Schulze Zur Wiesch; Axel Baumgarten; Stefan Christensen; Jürgen K Rockstroh; Stefan Mauss; GECCO Study Group

doi:10.1093/ofid/ofx158

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection

Open Forum Infect Dis. 2017 Jul 27;4(3):ofx158. doi: 10.1093/ofid/ofx158. eCollection 2017 Summer.

Authors

Christoph Boesecke^{1

2}, Patrick Ingiliz³, Florian Berger⁴, Thomas Lutz⁵, Knud Schewe⁶, Julian Schulze Zur Wiesch^{2

7}, Axel Baumgarten³, Stefan Christensen⁸, Jürgen K Rockstroh^{1

2}, Stefan Mauss⁴; GECCO Study Group

Affiliations

¹ University Hospital Bonn, Germany.
² German Centre for Infection Research (DZIF), Braunschweig, Germany.
³ Center for Infectiology Berlin, Germany.
⁴ Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
⁵ Infektiologikum, Frankfurt, Germany.
⁶ Infektionsmedizinisches Centrum Hamburg, Germany.
⁷ University Medical Center Hamburg-Eppendorf, Germany.
⁸ CIM Infectious Diseases, Münster, Germany.

Abstract

Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are less likely to achieve viral eradication.

Keywords: DAA; HCV treatment; HCV/HIV coinfection; chronic hepatitis C.